Skip to main content
. 2012 Sep 7;70(3):495–509. doi: 10.1007/s00018-012-1138-7

Fig. 7.

Fig. 7

Cardiac performance. a LVP variations. Data are expressed as changes of LVP values (mmHg) at the end of 120-min reperfusion with respect to baseline values for each group. Significant differences from control values, *p < 0.05 with respect to I/R, for Nesfatin-1-Post (100 pmol/L), Nesfatin-1-Post (100 pmol/L) + epsilon-V1-2 (1 μmol/L), and Nesfatin-1-PostC (100 pmol/L) + 5HD (100 μmol/L). b LVEDP variations. Data are expressed as changes of LVEDP variations (mmHg) at the end of 120-min reperfusion with respect to baseline values for each group. Significant differences from control values, *p < 0.05 with respect to I/R, for Nesfatin-1-Post, Nesfatin-1-Post + epsilon-V1-2, and Nesfatin-1-Post + 5HD. c Infarct size. The amount of necrotic tissue measured after 30-min global ischaemia and 120-min reperfusion is expressed as percentage of the left ventricle (IS/LV %); *p < 0.05 with respect to I/R and each antagonist group